Use of prasugrel vs clopidogrel and outcomes in patients with and without diabetes mellitus presenting with acute coronary syndrome undergoing percutaneous coronary intervention.

[1]  S. Pocock,et al.  Use of prasugrel vs clopidogrel and outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention in contemporary clinical practice: Results from the PROMETHEUS study , 2017, American heart journal.

[2]  G. Heinze,et al.  Clopidogrel, prasugrel, or ticagrelor use and clinical outcome in patients with acute coronary syndrome: A nationwide long-term registry analysis from 2009 to 2014. , 2017, International journal of cardiology.

[3]  Samin K. Sharma,et al.  Impact of Diabetes Mellitus on Ischemic Events in Men and Women After Percutaneous Coronary Intervention. , 2017, The American journal of cardiology.

[4]  S. Pocock,et al.  Incidence, Patterns, and Associations Between Dual-Antiplatelet Therapy Cessation and Risk for Adverse Events Among Patients With and Without Diabetes Mellitus Receiving Drug-Eluting Stents: Results From the PARIS Registry. , 2017, JACC. Cardiovascular interventions.

[5]  G. Filardo,et al.  Long Term Efficacy of Prasugrel versus Clopidogrel in Patients undergoing Percutaneous Coronary Intervention and Anticoagulated with Bivalirudin , 2016 .

[6]  Deepak L. Bhatt,et al.  Bleeding risk following percutaneous coronary intervention in patients with diabetes prescribed dual anti-platelet therapy. , 2016, American heart journal.

[7]  J. Rumsfeld,et al.  Prasugrel Use Following PCI and Associated Patient Outcomes: Insights From the National VA CART Program , 2016, Clinical Cardiology.

[8]  T. Engstrøm,et al.  Prasugrel or double-dose clopidogrel to overcome clopidogrel low-response – The TAILOR (Thrombocytes And IndividuaLization of ORal antiplatelet therapy in percutaneous coronary intervention) randomized trial , 2014, Platelets.

[9]  Eric D. Peterson,et al.  Early Clopidogrel Versus Prasugrel Use Among Contemporary STEMI and NSTEMI Patients in the US: Insights From the National Cardiovascular Data Registry , 2014, Journal of the American Heart Association.

[10]  A. Majluf-Cruz,et al.  Proinflammatory and Prothrombotic State in Subjects with Different Glucose Tolerance Status before Cardiovascular Disease , 2014, Journal of diabetes research.

[11]  H. Gurm,et al.  Contemporary Use of Prasugrel in Clinical Practice: Insights From the Blue Cross Blue Shield of Michigan Cardiovascular Consortium , 2013, Circulation. Cardiovascular quality and outcomes.

[12]  C. Terkelsen,et al.  Influence of diabetes mellitus on clinical outcomes following primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction. , 2012, The American journal of cardiology.

[13]  S. Stevens,et al.  Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial , 2010, European heart journal.

[14]  Christopher P Cannon,et al.  Diabetes and mortality following acute coronary syndromes. , 2007, JAMA.

[15]  D. Angiolillo,et al.  A Pharmacodynamic Comparison of Prasugrel Versus Ticagrelor in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease : The OPTIMUS ( Optimizing Antiplatelet Therapy in Diabetes Mellitus )-4 Study , 2016 .